Thibaud Portal, Aldena Therapeutics CEO

Medicxi backs siR­NA-fo­cused Alde­na Ther­a­peu­tics with $30M

With a $30 mil­lion in­fu­sion in­to Alde­na Ther­a­peu­tics by Medicxi, siR­NA-based ther­a­pies are mov­ing in­to der­ma­tol­ogy.

Alde­na, found­ed in 2021, plans to use its pipeline of six dif­fer­ent com­pounds on skin dis­eases fo­cus­ing on atopic der­mati­tis, vi­tili­go, alope­cia area­ta and pso­ri­a­sis. Three of the com­pounds will be ready for IND fil­ing next year, and two of the lead com­pounds will ini­tial­ly fo­cus par­tic­u­lar­ly on alope­cia area­ta and atopic der­mati­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.